- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Debra Boyer: Despite Setbacks, Some Pediatric Pulmonary Treatments Have Improved
Debra Boyer, MD, pediatric pulmonologist at Nationwide Children’s Hospital and co-chair of the American Thoracic Society International Conference Committee says that even though there are strides to be made in pediatric pulmonology, treatments for children with diseases, such as cystic fibrosis, have improved.
Adults and children with cystic fibrosis have seen treatment improvements, despite treatment limitations for other respiratory diseases, says Debra Boyer, MD, pediatric pulmonologist at Nationwide Children’s Hospital and co-chair of the American Thoracic Society International Conference Committee.
Transcript
How have pulmonology treatments for pediatric patients evolved?
Despite what I've said before about some of the limitations, things have evolved tremendously. I think cystic fibrosis (CF) is a prime example. I think all of the work that's been done on the CF modulator therapies; you can't even quantify certainly the emotions that have gone into this, but kids are doing so much better, and adults are now doing so much better with cystic fibrosis because of those early interventions. Similarly, maybe not as giant steps in things like asthma and some of the other conditions that we treat, you've seen some improvements in those as well. But cystic fibrosis is by far the one with the biggest steps that we've seen.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More
